Puma Biotechnology Inc (PBYI) exhibits 74.5% gross margins and 29.3% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 13.8x enterprise multiple and 4.8% implied options volatility.
Sustained 74.5% gross profitability converts into 16.3% operating margin and 29.3% ROIC, outpacing sector cost of capital.
ROIC: 29.3% // GM: 74.5%YoY revenue trajectory of -0.9% paired with 7.67% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -0.9% // FCF YLD: 7.67%Altman Z-Score of 0.20 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.20 // F-SCORE: 8/9Trading at 17.5x trailing P/E (16.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 17.5x // EV/EBITDA: 13.8xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $10.54 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 13.6% net margins.
NET MARGIN: 13.6% // D/E: 0.00x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for PBYI & activate live FRED threshold breach alerts.